Lehigh Valley news. Straight up.

The FDA is blocking some Olympus scopes from the U.S. The company, with North American operations in Lehigh County, raised its outlook anyway

Olympus raised its financial forecast while dealing with a U.S. FDA import alert affecting some medical scopes.

Fictional caricatured executive studies a forecast beside a medical endoscope
Editorial illustration
See the story visuallyThree quick visuals about this story

Visual summary

01 / Company outlook

Raised guidance

Olympus increased its annual forecast despite the FDA action.

02 / Local link

Lehigh County

The company bases its North American operations in Lehigh County.

03 / Still unknown

Local effect

The report did not say whether the FDA action affects local workers.

Want the full context? Read the article ↓

Olympus says it had a strong quarter. It also raised its outlook for the year, even with new trouble from the U.S. Food and Drug Administration.

The medical tech company has its main office in Japan. Its North American operations are based in Lehigh County.

Olympus went over its numbers this week for the second quarter of its 2027 business year.

"We continued to build upon the strong start we achieved in Q1," said Bob White, the company's president and CEO.

First, White talked about a warning letter the FDA sent Olympus in October.

The FDA sends warning letters when checks find problems, its website says. That can mean poor ways of making products or wrong directions for use.

The letter is tied to inspections of Olympus sites in the U.S., Japan and Europe in June 2025.

The FDA also put out an import alert. The alert stops future shipments of some Olympus products from coming into the U.S.

The list includes some models of scopes. Among them are bronchoscopes, laparoscopes, enteroscopes and ureterorenoscopes.

"After almost a year of our intensified efforts, new leadership and embedded expertise, we already see strides in addressing the FDA's areas of concern," White said.

In August, Olympus hired Brian Barry as its new chief quality officer. The company is also aiming for fixes across the whole system, not just small changes, WFMZ reported.

White said the company does not know how long the FDA will take to look at its latest reply. It also does not know when the FDA will inspect again.

"We know the process is going to take time and may not always be a linear one," White said.

Sales for the quarter were ¥269.2 billion, or about $1.69 billion. That was up 9% from a year earlier.

Problems like the FDA import alerts cut about ¥9 billion, or $56.8 million, from sales. That is what Michael Parenti, the company's chief financial officer, said.

Olympus also got ¥17.8 billion, or $111.3 million, back in U.S. tariff refunds. That money was left out of its adjusted profit numbers.

Adjusted earnings per share were ¥32. That was up 38% from a year earlier. Adjusted operating margin shows how much profit the company keeps from its sales. It was 17.8%, up 2.8 percentage points.

Olympus raised its forecast for the full year. The low end of its sales forecast went from ¥1,055 billion to ¥1,064.5 billion.

It now expects an adjusted operating margin of 15.7% to 16.7%, up from 15.2% to 16.7%. It expects adjusted earnings per share of ¥111 to ¥119, up from ¥106 to ¥119.

What do you think?

Join the conversation. A nickname is optional; comments are reviewed for spam and safety.

Want more Lehigh Valley news in your Google results? Add Yooumad as a preferred source.